01 January 1996
Effect of fluvastation on serum lipids in patients with essential hypertension
Judit Kaposci, Csaba Farsang, Gyula Pados, Katalin Detki, Zoltan Jarai, Janos Hollo, Zsuzsanna SebestyenMed Sci Monit 1996; 2(1): CR37-40 :: ID: 499518
Abstract
Background: to assess the efficacy and safety of fluvastatin in the treatment of hypercholesterolaemia in hypertensive patients (WHO I-II).
Material/Methods: An 8 week low-lipid diet was started if the fasting total cholesterol (TC) level was equal to or higher than 6.5 mM and the triglyceride (TG) level was lower than 4.6 mM. After the dietary period fluvastatin treatment was started, (20 mg daily) if the LDL-C level was >4.1 mM. Blood pressure, heart rate, as well as TC, HDL-C (HDL2-C, HDL3-C), apo A1, apo B and TG were measured at 4, 8 and 12 weeks of treatment. The daily dose of fluvastatin was increased to 40 mg, if a satisfactory lowering of LDL-C (3.5 mM) was not obtained after 4 weeks of treatment. The number of patients included in the study was 49, mean age 57.0±10.7 years (X&plusm;SD), the blood pressure 142 ±16/85 ±11 mmHg (systolic/diastolic respectively). The antihypertensive treatment remained unchanged.
Results: Thirty-six patients completed the study (6 patients were withdrawn because of lack of compliance, 7 patients were withdrawn at the end of the dietary period, because of the normalisation of lipid levels). Fluvastatin significantly reduced the TC level (from 7.22±0.88 mM to 5.99±0.98 mM), LDL-C (from 5.13±0.78 mM to 3.95±0.88 mM) and Apo B (from 0.97±0.21 mM to 0.85±0.15 mM), but did not influence the levels of HDL-C, Apo A1 and TG. The diastolic blood pressure decreased significantly by the end of the dietary period. After the administration of fluvastatin, the systolic blood pressure decreased significantly. Only minor side effects were observed.
Conclusions: Fluvastatin proved to be an effective and well tolerated drug in the treatment of hypercholesterolaemia in hypertensive patients.
Keywords: essential hypertension, fluvastatin, hypercholesterolaemia
579 0
Editorial
01 November 2023 : Editorial
Editorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is DeclaredDOI: 10.12659/MSM.942960
Med Sci Monit 2023; 29:e942960
In Press
29 Nov 2023 : Laboratory Research
CTRP13 Mitigates Endothelial Cell Ferroptosis via the AMPK/KLF4 Pathway: Implications for Atherosclerosis P...Med Sci Monit In Press; DOI: 10.12659/MSM.942733
28 Nov 2023 : Clinical Research
Impact of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography on Therapeutic Decisions and ...Med Sci Monit In Press; DOI: 10.12659/MSM.942122
28 Nov 2023 : Clinical Research
Long-Term Outcomes of Decompression and Grafting in Acute Pathological Proximal Femur Fractures in Children...Med Sci Monit In Press; DOI: 10.12659/MSM.943031
27 Nov 2023 : Clinical Research
Comparison of Outcomes from Emergency Admissions to a Major Trauma Center in Turkey of 1646 Elderly Patient...Med Sci Monit In Press; DOI: 10.12659/MSM.942916
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292